Literature DB >> 19837075

Azide and Tween-20 reduce binding to autoantibody epitopes of islet antigen-2; implications for assay performance and reproducibility.

Alistair J K Williams1, Michelle Somerville, Saba Rokni, Ezio Bonifacio, Liping Yu, George Eisenbarth, Beena Akolkar, Michael Steffes, Polly J Bingley.   

Abstract

Autoantibodies to islet antigen 2 (IA-2A) are important markers for predicting diabetes in children and young adults. Harmonization of IA-2A assay measurement is essential if results from different laboratories are to be compared. We investigated whether sodium azide, a bacteriostatic agent added to some assays, could affect IA-2A binding and thereby contribute to differences in IA-2A measurement between laboratories. Addition of 0.1% azide to assay buffer was found to reduce median IA-2A binding of 18 selected sera from IA-2A positive patients with type 1 diabetes and their relatives by 41% (range, 78 to -33%, p<0.001). The effect on binding was epitope specific; median IA-2A binding by 14 sera with antibodies to the protein tyrosine phosphatase region of IA-2 was reduced by 48% (range, 11 to 78%, p<0.001), while binding by 4 sera with antibodies specific to only the juxtamembrane region of IA-2 showed no change (median increase 16% (range 6 to 33%, p=0.125). When the Tween-20 concentration was reduced from 1% to 0.15% the median reduction in IA-2A binding with azide by the 18 sera was only 10% (range, -12 to 41%, p<0.001). Tween-20 also exerted an independent effect, since median IA-2A binding increased by 23% (range 3% to 86%, p<0.001) when Tween-20 concentration was reduced from 1% to 0.15% in the absence of azide. We conclude that common assay reagents such as azide and Tween-20 can strongly influence IA-2A binding in an epitope-related manner, and their use may explain some of the differences between laboratories in IA-2A measurement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837075      PMCID: PMC2830747          DOI: 10.1016/j.jim.2009.10.004

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Autoantibodies to IA-2 and IA-2 beta in insulin-dependent diabetes mellitus recognize conformational epitopes: location of the 37- and 40-kDa fragments determined.

Authors:  H Xie; B Zhang; Y Matsumoto; Q Li; A L Notkins; M S Lan
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

2.  Autoantibodies and associated T-cell responses to determinants within the 831-860 region of the autoantigen IA-2 in Type 1 diabetes.

Authors:  S M Weenink; J Lo; C R Stephenson; P A McKinney; R Ananieva-Jordanova; B Rees Smith; J Furmaniak; J M Tremble; H J Bodansky; M R Christie
Journal:  J Autoimmun       Date:  2009-05-15       Impact factor: 7.094

3.  Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials.

Authors:  P J Bingley; A J Williams; E A Gale
Journal:  Diabetes Care       Date:  1999-11       Impact factor: 19.112

4.  Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2.

Authors:  C J Hawkes; C Wasmeier; M R Christie; J C Hutton
Journal:  Diabetes       Date:  1996-09       Impact factor: 9.461

5.  Progression to diabetes in relatives with islet autoantibodies. Is it inevitable?

Authors:  S G Gardner; E A Gale; A J Williams; K M Gillespie; K E Lawrence; G F Bottazzo; P J Bingley
Journal:  Diabetes Care       Date:  1999-12       Impact factor: 19.112

6.  The World Health Organization International Collaborative Study for islet cell antibodies.

Authors:  A R Mire-Sluis; R Gaines Das; A Lernmark
Journal:  Diabetologia       Date:  2000-10       Impact factor: 10.122

7.  Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens.

Authors:  Massimo Bearzatto; Heike Naserke; Sandra Piquer; Kerstin Koczwara; Vito Lampasona; Alistair Williams; Michael R Christie; Polly J Bingley; Anette-G Ziegler; Ezio Bonifacio
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

8.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

9.  Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies.

Authors:  C F Verge; R Gianani; E Kawasaki; L Yu; M Pietropaolo; R A Jackson; H P Chase; G S Eisenbarth
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

10.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.

Authors:  Peter Achenbach; Katharina Warncke; Jürgen Reiter; Heike E Naserke; Alistair J K Williams; Polly J Bingley; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

  10 in total
  2 in total

1.  Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

Authors:  Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

2.  The core cysteines, (C909) of islet antigen-2 and (C945) of islet antigen-2β, are crucial to autoantibody binding in type 1 diabetes.

Authors:  Karen T Elvers; Ivey Geoghegan; Debbie K Shoemark; Vito Lampasona; Polly J Bingley; Alistair J K Williams
Journal:  Diabetes       Date:  2012-09-10       Impact factor: 9.461

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.